IBM Bet Big on Using Watson to Improve Cancer Care. It Has Fallen Short.

"Watson represents a technology breakthrough that can help physicians improve patient outcomes," said Herbert Chase, a professor of biomedical informatics at Columbia University, in a 2012 IBM press release. Six years and billions of dollars later, the diagnosis for Watson is gloomy. More than a dozen IBM partners and clients have halted or shrunk Watson's oncology-related projects. Watson cancer applications have had limited impact on patients, according to dozens of interviews with medical centers, companies and doctors who have used it, as well as documents reviewed by The Wall Street Journal. In many cases, the tools didn't add much value.